Cargando…
Post-treatment with the PPAR-γ agonist pioglitazone inhibits inflammation and bacterial growth during Klebsiella pneumonia
Agonists of peroxisome proliferator-activated receptor (PPAR)-γ have been suggested as potential adjuvant therapy in bacterial pneumonia because of their capacity to inhibit inflammation and enhance bacterial clearance. Previous studies only assessed the effects of pretreatment with these compounds,...
Autores principales: | Ramirez-Moral, Ivan, Ferreira, Bianca Lima, de Vos, Alex F., van der Poll, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375046/ https://www.ncbi.nlm.nih.gov/pubmed/34412637 http://dx.doi.org/10.1186/s12931-021-01823-8 |
Ejemplares similares
-
The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011) -
Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009) -
Carvacrol and PPARγ agonist, pioglitazone, affects inhaled paraquat-induced lung injury in rats
por: Amin, Fatemeh, et al.
Publicado: (2021) -
Effects of PPARγ Agonist Pioglitazone on Redox-Sensitive Cellular Signaling in Young Spontaneously Hypertensive Rats
por: Dovinová, Ima, et al.
Publicado: (2013) -
Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial
por: Anderson, J. R., et al.
Publicado: (2016)